Larimar Therapeutics closed at $2.76 on Nov 4, up 8.66%, 53.6% below its 52-week closing high. Volume of 2.0M shares was 1.27× its 20-day average (above normal).
Split-adjusted performance: -0.7% over one month, -33.5% over six months, -28.9% over one year.
Short interest was 14.7M shares at the Oct 15 settlement, down 4.6% from the prior report (23.8% of float, 8.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LRMRLarimar Therapeutics | $2.76 | +8.66% | −33.5% | — | — | — | $286.7M | |
| RCKTRocket Pharmaceuticals | $2.61 | +3.98% | −32.4% | — | — | — | $286.5M | Compare |
| FULCFulcrum Therapeutics | $3.77 | +0.80% | −47.0% | — | — | — | $288.0M | Compare |
| VOGXVogenx | $19.73 | −3.90% | — | — | — | — | $293.1M | Compare |
| TTRXTurn Therapeutics | $9.80 | +3.05% | +158.2% | — | — | — | $297.6M | Compare |
| BIOABioAge Labs | $5.95 | −0.17% | −67.8% | +1.6% | −1064.7% | — | $273.1M | Compare |
| EBSEmergent Biosolutions | $5.90 | −5.60% | −35.2% | −52.4% | −29.7% | — | $302.5M | Compare |
| SPRYARS Pharmaceuticals | $3.05 | 0.00% | −67.1% | +114.2% | −185.2% | — | $303.3M | Compare |
| QTTBQ32 Bio | $8.97 | +2.40% | +64.0% | — | — | 7.9 | $267.0M | Compare |
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
